A federal judge on Friday, Jan. 14, 2022 ordered Shkreli to return $64.6 million in profits he and his company reaped from inflating the price of the life-saving drug Daraprim and barred him from participating in the pharmaceutical industry for the rest of his life.
FILE - Former Turing Pharmaceuticals CEO Martin Shkreli attends the House Committee on Oversight and Reform Committee hearing on Capitol Hill in Washington, Feb. 4, 2016.
“Shkreli was no side player in, or a ‘remote, unrelated’ beneficiary of Vyera’s scheme,” Cote wrote in a 135-page opinion.
The trial record included evidence showing Shkreli kept in regular contact with company executives, even after he went to prison.
Zuckerberg “just happens to own the thing, and that’s the way it is,” Shkreli said in one of the recordings.
In 2019, Shkreli was sent to solitary confinement for a time after prison officials discovered him using a contraband smartphone to conduct business. »